The cluster is routine in size and pattern, all sales follow option exercises and are typical for C-suite insiders monetizing vested equity. No bearish signal here given the proportionality check. Monitor for any open-market purchases by insiders, which would be a stronger signal.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Aug 6 $25.22entry
- T+1 · 3mo ago +1.23%α +0.62% · $25.53
- T+5 · 3mo ago +7.81%α +6.60% · $27.19
- T+20 · due 3mo ago Pending
- T+60 · due 18d ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three C-suite insiders at Nurix Therapeutics (NRIX) sold a total of $534K in open-market shares over a 7-day window, with the Chief Legal Officer accounting for $382K of that total. The sales follow option exercises and are likely liquidity-driven, but the cluster of selling by the CSO, CFO, and CLO at prices near $23-25 per share warrants attention given the stock's recent run-up and the company's $2.6B market cap. The total value is only ~0.02% of market cap, making this a routine, non-material cluster by proportionality standards.
Key Financial Metrics
Key Facts
- Three C-suite insiders sold shares: CSO Gwenn Hansen ($109K), CLO Christine Ring ($382K), and CFO Hans van Houte ($183K)
- Total open-market sales of $534K represent ~0.02% of NRIX's $2.6B market cap
- All sales followed option exercises at $0 or $1.86-$8.72 strike prices, consistent with tax-covering or liquidity-driven selling
- No insider open-market purchases were reported in the cluster window
Financial Impact
Total insider sales of $534K, immaterial relative to $2.6B market cap
Risk Factors
- Insider selling could accelerate if the stock continues to rally, creating overhang
- No insider buying to signal conviction at current levels
- The cluster includes the CLO selling the most, legal officers often sell for diversification, not informational reasons
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NRIX-1785971197297 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $15.48 +2.04% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $15.48 +0.45% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $15.48 +4.31% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $15.48 +4.31% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $15.48 +4.31% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $15.48 −2.95% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $15.48 +2.95% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $15.48 −40.05% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $15.48 −40.05% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers